Eyeing Epilepsy Franchise, SAGE Therapeutics Raises $20M
This article was originally published in The Pink Sheet Daily
Executive Summary
ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.